

Swine Day 2017

Rowland Lab Research Update

Raymond (Bob) Rowland
K-State Swine Day Progress Report
November 17, 2016
Manhattan



**North American PRRS Symposium on PRRS,
Emerging and Foreign Animal Diseases
and National Swine Improvement Federation NAPRRS-NSIF
Joint Conference**

December 1-3, 2017
Intercontinental Chicago Magnificent Mile

November 24, 2017- Conference registration deadline



Genetic approaches for improving swine health in response to PRRSV infection

Raymond (Bob) Rowland- Kansas State University
browland@vet.k-state.edu

Collaborators


Randy Prather, University of Missouri- Genetically modified pigs that are disease resistant

Jack Dekkers, Iowa State University- Genomic markers for breeding disease resistance

Joan Lunney, ARS-USDA- Genetics of the response of pigs to infection



Porcine reproductive and respiratory syndrome (PRRS)



“Reproductive Failure of Unknown Etiology”

Kerry K. Keffaber, 1989, AASP

1. Influenza-like clinical signs
2. Mid- to late-term abortions
3. Pre-weaning mortality
4. Poor growth performance



Changes in Weight Distribution after Infection


\$14 billion in losses (\$600million/year)



PRRS is a production system disease

Endemic phase with outbreaks of severe disease

Persistence in a production system



2003-Eric Neumann


Stealthy

Easily transmitted

Persistent


Participates in polymicrobial diseases

Viremia



Day after infection

Persistence in a population and within a pig



The greatest cost of PRRSV is wasted feed

Sick and dead pigs
Slow growing pigs
Secondary infections




Corn Prices




Nutritional, Environmental and Social Impacts


Integrated approach for PRRS control



Vaccines
Detection
Ecology
Epidemiology
Biosecurity
Sociology




Feed efficiency
Feed formulation
Microbiome



Resistance
Tolerance
Resilience
Vaccine readiness
Genome editing

Getting back the 5-10% that PRRS takes



PRRS vaccines

- Modified live virus (MLV) vaccine introduced in the U.S. 1994- approved for use in PRRSV-infected herds
- MLV limitations-virus shedding, persistent infection, incomplete immune protection, inability to differentiate infected from vaccinated animals (DIVA), potential for reversion to virulence
- Killed vaccines are not effective
- Subversion of host immunity and antigenic variation have made further advances in vaccines difficult to achieve

Conclusions: Vaccines are a poor option for disease control and eradication- Vaccinated animals cannot be transported to PRRSV-free regions.




The application of genetics for improving animal health

- Marker selected breeding to improving response
- Modify genes involved in response to infection
 - Insertion of genes to promote resistance
 - Deletion of genes involved in virus susceptibility

“Genome Editing”

The favorable SSC4 marker, WUR, results in a 10% increase in weight and a decrease in viremia




Resistance
Tolerance
Resilience

Boddicker, et al. 2012. Evidence for a major QTL associated with host response to porcine reproductive and respiratory syndrome virus challenge. J Anim Sci. 90:1733-1746



Genetic modification CRISPR/Cas 9 system





Guide sequences direct where the genome is cut

Molecular scissors cut out DNA segment

Segment is removed and the DNA ends rejoined

Guide sequence

Knocking out CD163 by deleting 11 of 2.7 billion bases of the pig genome (Randy Prather)



Normal pig
CD163 is present

CD163 knockout pig
CD163 is absent

December 7, 2015


Gene-edited pigs are protected from porcine reproductive and respiratory syndrome virus

NATURE BIOTECHNOLOGY

Kristin M Whitworth¹, Raymond R R Rowland²,
Catherine L Ewen², Benjamin R Tribble²,
Maureen A Kerrigan², Ada G Cino-Ozuna²,
Melissa S Samuel¹, Jonathan E Lightner³,
David G McLaren³, Alan J Mileham³,
Kevin D Wells¹ & Randall S Prather¹


a CD163-Positive

b No CD163





No CD163
No key-lock
No PRRSV

a



b



Reproductive PRRS

Infection of pregnant gilt/sow at 90 days of gestation




Prevention of reproductive PRRS

The end of a disease

Table 1. *CD163* parental and fetal genotypes used in this study

Gilt No.	<i>CD163</i> Genotype			Day of Infection* ¹	Day of Gestation* ²	No. of Fetuses
	Parents		Fetus			
	Male	Dam				
138	+/+	+/+	+/+	91	106	16
139* ³	+/+	+/+	+/+	91	106	14
140	+/+	+/+	+/+	91	106	12
84	+/+	-/-	+/-	89	109	14
87	+/+	-/-	+/-	89	109	17
122	+/+	-/-	+/-	89	109	11
86	-/-	-/-	-/-	90	109	7
121	-/-	-/-	-/-	90	109	9


*¹ Gestation day when dams were infected
 *² Gestation day when fetuses were removed
 *³ PRRSV-infected dam aborted at 106 days of gestation



Prevention of reproductive PRRS

The end of a disease

Dam	Fetus	Dam No.	Genotype Dam Fetus	Right Uterine Horn	Left Uterine Horn
++	++	138 (3.6)	+/+ +/+	1 2 3 4 5 6 7 8 (1) (1) (5) (5) (1) (1) (1) (1) 6.9 N 5.3* 4.4 7.3 5.4* 1.7 N	9 10 11 12 13 14 15 16 (4) (1) (1) (3) (3) (3) (3) (5) 8.0 <1 5.4* 8.8 7.2 6.4* 7.1 8.0*
		140 (4.1)	+/+ +/+	1 2 3 4 5 (1) (1) (5) (2) (1) 5.7 4.0 ND 4.5 6.0	6 7 8 9 10 11 12 (2) (2) (5) (5) (5) (4) (1) 5.1* 2.3 7.3 5.1* 6.5 6.6 4.1
--	+/-	84 (N)	-/- +/-	1 2 3 4 5 6 7 8 (1) (1) (1) (1) (1) (1) (1) (1) N N N N N N N N	9 10 11 12 13 14 (1) (2) (1) (1) (1) (1) N N N N N N
		87 (N)	-/- +/-	1 2 3 4 5 6 7 8 9 10 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) N N N N N N N N N N	11 12 13 14 15 16 17 (1) (1) (2) (1) (1) (1) (1) N N N N N N N
		122 (N)	-/- +/-	1 2 3 4 5 (1) (1) (1) (1) (1) N N N N N	6 7 8 9 10 11 (1) (1) (1) (1) (1) (1) N N N N N N
--	-/-	86 (N)	-/- -/-	1 2 3 4 (1) (1) (1) (1) N N N N	5 6 7 (1) (1) (1) N N N
		121 (N)	-/- -/-	1 2 3 4 5 (1) (1) (1) (1) (1) N N N N N	6 7 8 9 (1) (1) (1) (1) N N N N



The end of a disease


- The absence of CD163 in the dam surrounds the developing fetus with a protective barrier, preventing infection with PRRSV
- The piglets are born with normal CD163 levels and are susceptible to PRRSV
- Still need that miracle vaccine



Mapping the regions where PRRSV interacts with CD163



Ana Stoian



NBAF



The NBAF, a new, state-of-the-art biosafety level (BSL) 3 & 4 facility located in Manhattan, KS, will enable the U.S. to conduct comprehensive research, develop vaccines and anti-virals, and provide enhanced diagnostic capabilities to protect our country from numerous foreign animal, emerging and zoonotic diseases to assist in protecting our food supply and the nation's agriculture economy and public health.

NBAF-associated projects in the Rowland lab (Biosecurity Research Institute)

African swine fever virus (ASFV) and classical swine fever virus (CSFV)

Vaccines

Diagnostics

Genetics of disease resistance

Risks for introduction



PHGC

Co-Directors
USDA ARS BARC
Joan Lunney
Kansas State University
RRR (Bob) Rowland
Iowa State University
Jack Dekkers



Kansas NBAF Transition Fund

- NIFA award #2013-68004-20362
- National Pork Board
- Genome Canada
- LLNL

pork
checkoff

USDA | **NIFA**

